Low-barrier hydrogen bonds have been recently hypothesized to be involved in providing the energy required by enzymes for catalysis. These very strong, low-barrier hydrogen bonds exhibit very low field proton NMR signals (16-20 ppm) and low deuterium fractionation factors. The mechanism of enolase is believed to pass through a carbanion intermediate, which may be stabilized by such a low-barrier hydrogen bond present in the intermediate but not ground state. It has been demonstrated by Weiss, et al. (JACS, 1987) that the fractionation factor for the proton transferred from C-2 of D-TSP (a competitive inhibitor of enolase) to the catalytic base is far below unity. Because no cysteine residues are present in the catalytic site to explain this finding, as observed from x-ray crystal structure, it has been hypothesized that this result suggests the presence of a low-barrier hydrogen bond. Thus, proton NMR will be used to search for a low field signal indicative of such a low-barrier hydrogen bond. Methylene phosphoenolpyruvate, a slow substrate for enolase, and tartronate semialdehyde phosphate, a dead end inhibitor, will be employed for the studies. The use of such inhibitors in which the intermediate may be present in appreciable amounts is hoped to allow one to observe the low field signal representative of a low-barrier hydrogen bond. A low field proton NMR signal has been observed in chymotrypsin by Robillard, et al. (J. Mol. Biol., 1972), which has been postulated to represent a low-barrier hydrogen bond.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Biotechnology Resource Grants (P41)
Project #
3P41RR002301-15S1
Application #
6120914
Study Section
Project Start
1999-03-01
Project End
2000-02-29
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
15
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Travers, Timothy; López, Cesar A; Van, Que N et al. (2018) Molecular recognition of RAS/RAF complex at the membrane: Role of RAF cysteine-rich domain. Sci Rep 8:8461
Thomas, Nathan E; Wu, Chao; Morrison, Emma A et al. (2018) The C terminus of the bacterial multidrug transporter EmrE couples drug binding to proton release. J Biol Chem 293:19137-19147
Assadi-Porter, Fariba M; Radek, James; Rao, Hongyu et al. (2018) Multimodal Ligand Binding Studies of Human and Mouse G-Coupled Taste Receptors to Correlate Their Species-Specific Sweetness Tasting Properties. Molecules 23:
Wijayatunga, Nadeeja N; Sams, Valerie G; Dawson, John A et al. (2018) Roux-en-Y gastric bypass surgery alters serum metabolites and fatty acids in patients with morbid obesity. Diabetes Metab Res Rev 34:e3045
Assadi-Porter, Fariba M; Reiland, Hannah; Sabatini, Martina et al. (2018) Metabolic Reprogramming by 3-Iodothyronamine (T1AM): A New Perspective to Reverse Obesity through Co-Regulation of Sirtuin 4 and 6 Expression. Int J Mol Sci 19:
Dominguez, Eddie; Zarnowski, Robert; Sanchez, Hiram et al. (2018) Conservation and Divergence in the Candida Species Biofilm Matrix Mannan-Glucan Complex Structure, Function, and Genetic Control. MBio 9:
Franco, Aldo; Dovell, Sanaz; Möller, Carolina et al. (2018) Structural plasticity of mini-M conotoxins - expression of all mini-M subtypes by Conus regius. FEBS J 285:887-902
Wales, Jessica A; Chen, Cheng-Yu; Breci, Linda et al. (2018) Discovery of stimulator binding to a conserved pocket in the heme domain of soluble guanylyl cyclase. J Biol Chem 293:1850-1864
Selen Alpergin, Ebru S; Bolandnazar, Zeinab; Sabatini, Martina et al. (2017) Metabolic profiling reveals reprogramming of lipid metabolic pathways in treatment of polycystic ovary syndrome with 3-iodothyronamine. Physiol Rep 5:
Mong, Surin K; Cochran, Frank V; Yu, Hongtao et al. (2017) Heterochiral Knottin Protein: Folding and Solution Structure. Biochemistry 56:5720-5725

Showing the most recent 10 out of 613 publications